Gabriele, Rebecca MC;
Abel, Emily;
Fox, Nick C;
Wray, Selina;
Arber, Charles;
(2022)
Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities.
Frontiers in Neuroscience
, 16
, Article 835645. 10.3389/fnins.2022.835645.
Preview |
Text
fnins-16-835645.pdf - Published Version Download (1MB) | Preview |
Abstract
Amyloid precursor protein (APP) and its cleavage fragment Amyloid-β (Aβ) have fundamental roles in Alzheimer’s disease (AD). Genetic alterations that either increase the overall dosage of APP or alter its processing to favour the generation of longer, more aggregation prone Aβ species, are directly causative of the disease. People living with one copy of APP are asymptomatic and reducing APP has been shown to lower the relative production of aggregation-prone Aβ species in vitro. For these reasons, reducing APP expression is an attractive approach for AD treatment and prevention. In this review, we will describe the structure and the known functions of APP and go on to discuss the biological consequences of APP knockdown and knockout in model systems. We highlight progress in therapeutic strategies to reverse AD pathology via reducing APP expression. We conclude that new technologies that reduce the dosage of APP expression may allow disease modification and slow clinical progression, delaying or even preventing onset.
| Type: | Article |
|---|---|
| Title: | Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fnins.2022.835645 |
| Publisher version: | http://doi.org/10.3389/fnins.2022.835645 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10145095 |
Archive Staff Only
 |
View Item |
